Strategies to prevent contrast nephropathy

Minerva Cardioangiologica

Volumn 53, Issue 5, 2005, Pages 445-463

  Oudemans Van Straaten, H M ^a  

^a Onze Lieve Vrouwe Gasthuis ^*  (Netherlands)

Author keywords

Angiography; Contrast media; Kidney diseases; Kidney failure, acute, prevention and control

Indexed keywords

ACETYLCYSTEINE; ACICLOVIR; AMINOGLYCOSIDE; AMPHOTERICIN B; ASCORBIC ACID; ATRIAL NATRIURETIC FACTOR; BICARBONATE; CISPLATIN; CONTRAST MEDIUM; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; DOPAMINE; ENDOTHELIN RECEPTOR ANTAGONIST; FENOLDOPAM MESILATE; FOSCARNET; FUROSEMIDE; MANNITOL; NITRENDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PROSTAGLANDIN E1; SODIUM CHLORIDE; THEOPHYLLINE;

ACUTE KIDNEY FAILURE; ANGIOCARDIOGRAPHY; APOPTOSIS; CARDIOVASCULAR DISEASE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTRAST NEPHROPATHY; CYTOTOXICITY; DISEASE CONTROL; DISEASE SEVERITY; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; HEART FAILURE; HEMOFILTRATION; HUMAN; INCIDENCE; KIDNEY BLOOD VESSEL; KIDNEY FAILURE; KIDNEY ISCHEMIA; META ANALYSIS; MORBIDITY; MORTALITY; NEPHROTOXICITY; OSMOLALITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROPHYLAXIS; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; TISSUE INJURY; VASOCONSTRICTION;

ACETYLCYSTEINE; ASCORBIC ACID; CONTRAST MEDIA; HUMANS; KIDNEY FAILURE, ACUTE; PHOSPHODIESTERASE INHIBITORS; PROSTAGLANDINS; THEOPHYLLINE;

EID: 28444471279     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (124)

1. Rich MW, Crecelius CA. Incidence, risk factors, and clinical course of acute renal insufficiency after cardiac catheterization in patients 70 years of age or older. A prospective study. Arch Intern Med 1990;150:1237-42.
2. Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality. A cohort analysis. JAMA 1996;275:1489-94.
3. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997;103:368-75.
4. Aronow HD, Peyser PA, Eagle KA, Bates ER, Werns SW, Russman PL et al. Predictors of length of stay after coronary stenting. Am Heart J 2001;142:799-805.
5. Gruberg L, Mehran R, Dangas G, Mintz GS, Waksman R, Kent KM et al. Acute renal failure requiring dialysis after percutaneous coronary interventions. Catheter Cardiovasc Interv 2001;52:409-16.
6. Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary Intervention. Circulation 2002;105:2259-64.
7. Guitterez NV, Diaz A, Timmis GC, O'Neill WW, Stevens MA, Sandberg KR et al. Determinants of serum creatinine trajectory in acute contrast nephropathy. J Interv Cardiol 2002;15:349-54.7.
8. Manske CL, Sprafka JM, Strony JT, Wang Y. Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography. Am J Med 1990;89:615-20.
9. Dellinger RP, Carlet JM, Masur H, Gerlach H. Introduction to the Surviving Sepsis Campaign Guidelines. Crit Care Med 2004;32 (Suppl):S446-7.
10. Brezis M, Rosen S. Hypoxia of the renal medulla - its implications for disease. N Engl J Med 2003;332:647-55.
11. Arakawa K, Suzuki H, Naitoh M, Matsumoto A, Hayashi K, Matsuda H et al. Role of adenosine in the renal responses to contrast medium. Kidney Int 1996;49:1199-206.
12. Erley CM, Heyne N, Rossmeier S, Vogel T, Risler T, Osswald H. Adenosine and extracellular volume in radiocontrast media-induced nephropathy. Kidney Int 1998;67 Suppl:S192-4.
13. Russo D, Minutolo R, Cianciaruso B, Memoli B, Conte G, De Nicola L. Early effects of contrast media on renal hemodynamics and tubular function in chronic renal failure. J Am Soc Nephrol 1995;6:1451-8.
14. Erley CM, Heyne N, Burgert K, Langanke J, Risler T, Osswald H. Prevention of radiocontrast-induced nephropathy by adenosine antagonists in rats with chronic nitric oxide deficiency. J Am Soc Nephrol 1997;8:1125-32.
15. Gambaro G, Perazella MA. Adverse renal effects of anti-inflammatory agents: evaluation of selective and nonselective cyclooxygenase inhibitors. J Intern Med 2003;253:643-52.
16. Bakris GL, Lass N, Gaber AO, Jones JD, Burnett JC Jr. Radiocontrast medium-induced declines in renal function: a role for oxygen free radicals. Am J Physiol 1990;258:F115-20.
17. Welch WJ, Tojo A, Wilcox CS. Roles of NO and oxygen radicals in tubuloglomerular feedback in SHR. Am J Physiol Renal Physiol 2000;278:F769-76.
18. Katholi RE, Woods WT Jr, Taylor GJ, Deitrick CL, Womack KA et al. Oxygen free radicals and contrast nephropathy. Am J Kidney Dis 1998;32:64-71.
19. Yoshioka T, Fogo A, Beckman JK. Reduced activity of antioxidant enzymes underlies contrast media-induced renal injury in volume depletion. Kidney Int 1992;41:1008-15.
20. Hizoh I, Strater J, Schick CS, Kubler W, Haller C. Radiocontrast-induced DNA fragmentation of renal tubular cells in vitro: role of hypertonicity. Nephrol Dial Transplant 1998;13:911-8.
21. Zager RA, Johnson AC, Hanson SY. Radiographic contrast media-induced tubular injury: evaluation of oxidant stress and plasma membrane integrity. Kidney Int 2003;64:128-39.
22. Scolari F, Tardanico R, Zani R, Pola A, Viola BF, Movilli E et al. Cholesterol crystal embolism: a recognizable cause of renal disease. Am J Kidney Dis 2000;36:1089-109.
23. Bhaskaran M, Reddy K, Radhakrishanan N, Franki N, Ding G, Singhal PC. Angiotensin II induces apoptosis in renal proximal tubular cells. Am J Physiol Renal Physiol 2002;284:F955-65.
24. Efrati S, Dishy V, Averbukh M, Blatt A, Krakover R, Weisgarten J et al. The effect of N-acetylcysteine on renal function, nitric oxide, and oxidative stress after angiography. Kidney Int 2003;64:2182-7.
25. Katholi RE, Taylor GJ, McCann WP, Woods WT Jr, Womack KA, McCoy CD et al. Nephrotoxicity from contrast media: attenuation with theophylline. Radiology 1995;195:17-22.
26. Heyman SN, Clark BA, Kaiser N, Spokes K, Rosen S, Brezis M et al. Radiocontrast agents induce endothelin release in vivo and in vitro. J Am Soc Nephrol 1992;3:58-65.
27. Murphy ME, Tublin ME, Li S. Influence of contrast media on the response of rat renal arteries to endothelin and nitric oxide: influence of contrast media. Invest Radiol 1998;33:356-65.
28. Bonegio R, Lieberthal W. Role of apoptosis in the pathogenesis of acute renal failure. Curr Opin Nephrol Hypertens 2002;11:301-8.
29. Liu KD. Molecular mechanisms of recovery from acute renal failure. Crit Care Med 2003;31(8 Suppl):S572-81.
30. Yano T, Itoh Y, Sendo T, Kubota T, Oishi R. Cyclic AMP reverses radiocontrast media-induced apoptosis in LLC-PK1 cells by activating A kinase/PI3 kinase. Kidney Int 2003;64:2052-63.
31. Alamartine E, Phayphet M, Thibaudin D, Barral FG, Veyret C. Contrast medium-induced acute renal failure and cholesterol embolism after radiological procedures: incidence, risk factors, and compliance with recommendations. Eur J Intern Med 2003;14:426-31.
32. Fukumoto Y, Tsutsui H, Tsuchihashi M, Masumoto A, Takeshita A. The incidence and risk factors of cholesterol embolization syndrome, a complication of cardiac catheterization: a prospective study. J Am Coll Cardiol 2003;42:211-6.
33. Sheikhzadeh A, Ehlermann P. Atheromatous disease of the thoracic aorta and systemic embolism. Clinical picture and therapeutic challenge. Z Kardiol 2004;93:10-7.
34. Barrett BJ, Parfrey PS. Prevention of nephrotoxicity induced by radiocontrast agents. N Engl J Med 1994;331:1449-50.
35. Thomsen HA, Morcos SK. Contrast media and the kidney: European Society of Urogenital Radiology (ESUR) Guidelines. Br J Radiol 2003;76:513-8.
36. Sadeghi HM, Stone GW, Grines CL, Mehran R, Dixon SR, Lansky AJ et al. Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. Circulation 2003;108:2769-75.
37. Nikolsky E, Mehran R, Lasic Z, Mintz GS, Lansky AJ, Na Y et al. Low hematocrit predicts contrast-induced nephropathy after percutaneous coronary interventions. Kidney Int 2005;67:706-13.
38. Mueller C, Buerkle G, Buettner HJ, Petersen J, Perruchoud AP, Eriksson U et al. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 2002;162: 329-36.
39. Oldemeyer JB, Biddle WP, Wurdeman RL, Mooss AN, Cichowski E, Hilleman DE. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography. Am Heart J 2003;146:E23.
40. Bartholomew BA, Harjai KJ, Dukkipati S, Boura JA, Yerkey MW, Glazier S et al. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol 2004;93:1515-9.
41. Weisberg LS, Kurnik PB, Kurnik BR. Risk of radiocontrast nephropathy in patients with and without diabetes mellitus. Kidney Int 1994;45:259-65.
42. Mueller C, Buerkle G, Perruchoud AP, Buettner HJ. Female sex and risk of contrast nephropathy after percutaneous coronary intervention. Can J Cardiol 2004;20: 505-9.
43. Choudhury D, Ahmed Z. Drug-induced nephrotoxicity. Med Clin North Am 1997;81:705-17.
44. Baliga R, Ueda N, Walker PD, Shah SV. Oxidant mechanisms in toxic acute renal failure. Drug Metab Rev 1999;31:971-97.
45. McCarthy CS, Becker JA. Multiple myeloma and contrast media. Radiology 1992;183:519-21.
46. Sakhuja V, Jha V, Varma S, Joshi K, Gupta KL, Sud K et al. Renal involvement in multiple myeloma: a 10-year study. Ren Fail 2000;22:465-77.
47. Rashid ST, Salman M, Myint F, Baker DM, Agarwal S, Sweny P et al. Prevention of contrast-induced nephropathy in vascular patients undergoing angiography: a randomized controlled trial of intravenous N-acetylcysteine. J Vasc Surg. 2004;40:1136-41.
48. Brinker J. What every cardiologist should know about intravascular contrast. Rev Cardiovasc Med 2003;4: S19-27.
49. Barrett BJ, Carlisle EJ. Meta-analysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. Radiology 1993;188:171-8.
50. Rudnick MR, Goldfarb S, Wexler L, Ludbrook PA, Murphy MJ, Halpern EF et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Coop. Study. Kidney Int 1995;47:254-61.
51. Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Berg KJ. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 2003;348: 491-9.
52. Erley CM, Bader BD, Berger ED, Tuncel N, Winkler S, Tepe G et al. Gadolinium-based contrast media compared with iodinated media for digital subtraction angiography in azotaemic patients. Nephrol Dial Transplant 2004;19:2526-31.
53. Briguori C, Manganelli F, Scarpato P, Elia PP, Golia B, Riviezzo G et al. Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol 2002;40: 298-303.
54. Huber W, Schipek C, Ilgmann K, Page M, Hennig M, Wacker A et al. Effectiveness of theophylline prophylaxis of renal impairment after coronary angiography in patients with chronic renal insufficiency. Am J Cardiol 2003;91:1157-62.
55. Diaz-Sandoval LJ, Kosowsky BD, Losordo DW. Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). Am J Cardiol 2002;89:356-8.
56. Abizaid AS, Clark CE, Mintz GS, Dosa S, Popma JJ, Pichard AD et al. Effects of dopamine and aminophylline on contrast-induced acute renal failure after coronary angioplasty in patients with preexisting renal insufficiency. Am J Cardiol 1999;83:260-3.
57. Gupta RK, Kapoor A, Tewari S, Sinha N, Sharma RK. Captopril for prevention of contrast-induced nephropathy in diabetic patients: a randomised study. Indian Heart J 1999;51:521-6.
58. Nawaz S, Cleveland T, Gaines PA, Chan P. Clinical risk associated with contrast angiography in metformin treated patients: a clinical review. Clin Radiol 1998;53: 342-4.
59. Trivedi HS, Moore H, Nasr S, Aggerwal K, Agrawal A, Goel P et al. A randomised prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity. Nephron Clin Pract 2003;93: C29-34.
60. Solomon R, Werner C, Mann D, D'Elia J, Silva P. Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med 1994;331:1416-20.
61. Stevens MA, McCullough PA, Tobin KJ, Speck JP, Westveer DC, Guido-Allen DA et al. A prospective randomized trial of prevention measures in patients at risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. J Am College Cardiol 1999;33:403-11.
62. Merten GJ, Burgess WP, Gray LV, Holleman JH, Roush TS, Kowalchuk GJ et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA 2004;29:2328-34.
63. Bader BD, Berger ED, Heede MB, Silberbaur I, Duda S, Risler T et al. What is the best hydration regimen to prevent contrast media-induced nephrotoxicity? Clin Nephrol 2004;62:1-7.
64. Erley CM. Does hydration prevent radiocontrast-induced acute renal failure? Nephrol Dial Transplant 1999;14:1064-6.
65. Drager LF, Andrade L, Barros de Toledo JF, Laurindo FR, Machado Cesar LA, Seguro AC. Renal effects of N-acetylcysteine in patients at risk for contrast nephropathy: decrease in oxidant stress-mediated renal tubular injury. Nephrol Dial Transplant 2004;19:1803-7.
66. Conesa EL, Valero F, Nadal JC, Fenoy FJ, Lopez B, Arregui B et al. N-acetyl-L-cysteine improves renal medullary hypoperfusion in acute renal failure. Am J Physiol Regul Integr Comp Physiol 2001;281:R730-7.
67. Pena LR, Hill DB, McClain CJ. Treatment with glutathione precursor decreases cytokine activity. JPEN J Parenter Enteral Nutr 1999;23:1-6.
68. Hoffmann U, Fischereder M, Kruger B, Drobnik W, Kramer BK. The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol 2004;15:407-10.
69. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000;343:180-4.
70. Allaqaband S, Tumuluri R, Malik AM, Gupta A, Volkert P, Shalev Y et al. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. Catheter Cardiovasc Interv 2002;57:279-83.
71. Durham JD, Caputo C, Dokko J, Zaharakis T, Pahlavan M, Keltz J et al. A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int 2002;62:2202-7.
72. Shyu KG, Cheng JJ, Kuan P. Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J Am Coll Cardiol 2002;40:1383-8.
73. Kay J, Chow WH, Chan TM, Lo SK, Kwok OH, Yip A et al. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. JAMA 2003;289:553-8.
74. MacNeill BD, Harding SA, Bazari H, Patton KK, Colon-Hernadez P, DeJoseph D et al. Prophylaxis of contrast-induced nephropathy in patients undergoing coronary angiography. Catheter Cardiovasc Interv 2003;60: 458-61.
75. Goldenberg I, Shechter M, Matetzky S, Jonas M, Adam M, Pres H et al. Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography. A randomized controlled trial and review of the current literature. Eur Heart J 2004;25:212-8.
76. Fung JW, Szeto CC, Chan WW, Kum LC, Chan AK, Wong JT et al. Effect of N-acetylcysteine for prevention of contrast nephropathy in patients with moderate to severe renal insufficiency: a randomized trial. Am J Kidney Dis 2004;43:801-8.
77. Ochoa A, Pellizzon G, Addala S, Grines C, Isayenko Y, Boura J et al. Abbreviated dosing of N-acetylcysteine prevents contrast-induced nephropathy after elective and urgent coronary angiography and intervention. J Interv Cardiol 2004;17:159-65.
78. Miner SE, Dzavik V, Nguyen-Ho P, Richardson R, Mitchell J, Atchison D et al. N-acetylcysteine reduces contrast-associated nephropathy but not clinical events during long-term follow-up. Am Heart J 2004;148:690-5.
79. Gomes VO, Poli de Figueredo CE, Caramori P, Lasevitch R, Bodanese LC, Araujo A et al. N-acetylcysteine does not prevent contrast induced nephropathy after cardiac catheterisation with an ionic low osmolality contrast medium: a multicentre clinical trial. Heart. 2005;91: 774-8.
80. Baker CS, Wragg A, Kumar S, De Palma R, Baker LR, Knight CJ. A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. J Am Coll Cardiol 2003;41:2114-8.
81. Kefer JM, Hanet CE, Boitte S, Wilmotte L, De Kock M. Acetylcysteine, coronary procedure and prevention of contrast-induced worsening of renal function: which benefit for which patient? Acta Cardiol 2003;58:555-60.81.
82. Webb JG, Pate GE, Humphries KH, Buller CE, Shalansky S, Al Shamari A et al. A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect. Am Heart J 2004;148: 422-9.
83. Briguori C, Colombo A, Violante A, Balestrieri P, Manganelli F, Paolo Elia P et al. Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity. Eur Heart J 2004;25:206-11.
84. Birck R, Krzossok S, Markowetz F, Schnulle P, van der Woude FJ, Braun C. Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet 2003;362: 598-603.
85. Isenbarger DW, Kent SM, O'Malley PG. Meta-analysis of randomized clinical trials on the usefulness of acetylcysteine for prevention of contrast nephropathy. Am J Cardiol 2003;92:1454-8.
86. Alonso A, Lau J, Jaber BL, Weintraub A, Sarnak MJ. Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease: a meta-analysis of randomized, controlled trials. Am J Kidney Dis 2004;43:1-9.
87. Misra D, Leibowitz K, Gowda RM, Shapiro M, Khan IA. Role of N-acetylcysteine in prevention of contrast-induced nephropathy after cardiovascular procedures: a meta-analysis. Clin Cardiol 2004;27:607-10.
88. Nishiyama A, Edward W, Inscho EW, Navar LG. Interactions of adenosine A1 and A2a receptors on renal microvascular reactivity Am J Physiol Renal Physiol 2001;280:F406-14.
89. Lee HT, Emala CW. Protective effects of renal ischemic preconditioning and adenosine pre-treatment: role of A1 and A3 receptors. Am J Physiol Renal Physiol 2000; 278:F380-7.
90. Erley CM, Duda SH, Schlepckow S, Koehler J, Huppert PE, Strohmaier WL et al. Adenosine antagonist theophylline prevents the reduction of glomerular filtration rate after contrast media application. Kidney Int 1994;45:1425-31.
91. Kolonko A, Wiecek A, Kokot F. The nonselective adenosine antagonist theophylline does prevent renal dysfunction induced by radiographic contrast agents. J Nephrol 1998;11:151-6.
92. Erley CM, Duda SH, Rehfuss D, Scholtes B, Bock J, Muller C et al. Prevention of radiocontrast-media-induced nephropathy in patients with pre-existing renal insufficiency by hydration in combination with the adenosine antagonist theophylline. Nephrol Dial Transplant 1999;14:1146-9.
93. Huber W, Ilgmann K, Page M, Hennig M, Schweigart U, Jeschke B et al. Effect of theophylline on contrast material-nephropathy in patients with chronic renal insufficiency: controlled, randomized, double-blinded study. Radiology 2002;223:772-9.
94. apoor A, Kumar S, Gulati S, Gambhir S, Sethi RS, Sinha N. The role of theophylline in contrast-induced nephropathy: a case-control study. Nephrol Dial Transplant 2002;17:1936-41.
95. Bader BD, Berger ED, Rossmann S, Risler T, Erley CM. Prevention of contrast media-induced acute renal failure in patients with severe impaired renal function - Theophylline versus N-acetylcysteine. J Am Soc Nephrol 2002, 13 (Abstract SA-P0887).
96. Ix JH, McCulloch CE, Chertow GM. Theophylline for the prevention of radiocontrast nephropathy: a meta-analysis. Nephrol Dial Transplant 2004;19:2747-53.
97. Bagshaw SM, Ghali WA. Theophylline for prevention of contrast-induced nephropathy: a systematic review and meta-analysis. Arch Intern Med 2005 May 23;165: 1087-93.
98. Spargias K, Alexopoulos E, Kyrzopoulos S, Iacovis P, Greenwood DC, Manginas A et al. Ascorbic acid prevents Contrast-mediated Nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation 2004;110:2837-42.
99. Wang YX, Jia YF, Chen KM, Morcos SK. Radiographic contrast media induced nephropathy: experimental observations and the protective effect of calcium channel blockers. Br J Radiol 2001;74:1103-8.
100. Bakris GL, Burnett JC. A role for calcium in radio-contrast-induced reductions in renal hemodynamics. Kidney Int 1985;27:465-8.
101. Neumayer HH, Junge W, Kufner A, Wenning A. Prevention of radiocontrast-media-induced nephrotoxicity by the calcium channel blocker nitrendipine: a prospective randomised clinical trial. Nephrol Dial Transplant 1989;4:1030-6.
102. Khoury Z, Schlicht JR, Como J, Karschner JK, Shapiro AP, Mook WJ et al. The effect of prophylactic nifedipine on renal function in patients administered contrast media. Pharmacotherapy 1995;15:59-65.
103. Sward K, Valsson F, Sellgren J, Ricksten SE. Differential effects of human atrial natriuretic peptide and furosemide on glomerular filtration rate and renal oxygen consumption in humans. Intensive Care Med 2005;31:79-85.
104. Weisberg LS, Kurnik PB, Kurnik BR. Dopamine and renal blood flow in radiocontrast-induced nephropathy in humans. Ren Fail 1993;15:61-8.
105. Gare M, Haviv YS, Ben-Yehuda A, Rubinger D, Bdolah-Abram T, Fuchs S et al. The renal effect of low-dose dopamine in high-risk patients undergoing coronary angiography. J Am Coll Cardiol 1999;34:1682-8.
106. Bakris GL, Lass NA, Glock D. Renal hemodynamics in radiocontrast medium-induced renal dysfunction: a role of dopamine-1 receptors. Kidney Int 1999;56: 205-10.
107. Madyoon H. Clinical experience with the use of fenoklopam for prevention of radiocontrast nephropathy in high-risk patients. Rev Cardiovasc Med 2001;2 Suppl 1:S26-30.
108. Kini AA, Sharma SK. Managing the high-risk patient: experience with fenoldopam, a selective dopamine receptor agonist, in prevention of radiocontrast nephropathy during percutaneous coronary intervention. Rev Cardiovasc Med 2001;2 Suppl 1:S19-25.
109. Tumlin JA, Wang A, Murray PT, Mathur VS. Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: a pilot trial in the prevention of contrast nephropathy. Am Heart J 2002; 143:894-903.
110. Stone GW, McCullough PA, Tumlin JA, Lepor NE, Madyoon H, Murray P et al. CONTRAST Investigators. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA 2003;290:2284-91.
111. Briguori C, Colombo A, Airoldi F, Violante A, Castelli A, Balestrieri P et al. N-Acetylcysteine versus fenoldopam mesylate to prevent contrast agent-associated nephrotoxicity. J Am Coll Cardiol 2004;44:762-5.
112. Kurnik BR, Allgren RL, Genter FC, Solomon RJ, Bates ER, Weisberg LS. Prospective study of atrial natriuretic peptide for the prevention of radiocontrast-induced nephropathy. Am J Kidney Dis 1998;31:674-80.
113. Paller MS, Manivel JC. Prostaglandins protect kidneys against ischemic and toxic injury by a cellular effect. Kidney Int 1992;42:1345-54.
114. Koch JA, Plum J, Grabensee B, Modder U. Prostaglandin E1: a new agent for the prevention of renal dysfunction in high risk patients caused by radiocontrast media? PGE1 Study Group. Nephrol Dial Transplant 2000;15:43-9.
115. Clark RA, Kim D, Epstein FH. Endothelin and atrial natriuretic peptide levels following radiocontrast exposure in humans. Am J Kidney Dis 1997;30:82-6.
116. Heyman SN, Clark BA, Cantley L, Spokes K, Rosen S. Brezis M et al. Effects of ioversol versus iothalamate on endothelin release and radiocontrast nephropathy. Invest Radiol 1993;28:313-8.
117. Fujisaki K, Kubo M, Masuda K, Tokumoto M, Hirakawa M, Ikeda H et al. Infusion of radiocontrast agents induces exaggerated release of urinary endothelin in patients with impaired renal function. Clin Exp Nephrol 2003;7:279-83.
118. Liss P, Carlsson PO, Nygren A, Palm F, Hansell P. ET-A receptor antagonist BQ 123 prevents radiocontrast mediator induced renal medullary hypoxia. Acta Radiol 2003;44:111-7.
119. Wang A, Holcslow T, Bashore TM, Freed MI, Miller D, Rudnick MR et al. Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism. Kidney Int 2000;57:1675-80.
120. Halor JL, Morcos SH. Endothelin antagonism and contrast nephropathy. Kidney Int 2000;58:2239.
121. Noronha JL, Matuschak GM. Magnesium in critical illness: metabolism, assessment, and treatment. Intensive Care Med 2002;28:667-79.
122. Schindler R, Stahl C, Venz S, Ludat K, Krause W, Frei U. Removal of contrast media by different extracorporeal treatments. Nephrol Dial Transplant 2001;16: 1471-4.
123. Vogt B, Ferrari P, Schonholzer C, Marti HP, Mohaupt M, Wiederkehr M et al. Prophylactic hemodialysis after radiocontrast media in patients with renal insufficiency is potentially harmful. Am J Med 2001;111: 692-8.
124. Marenzi G, Marana I, Lauri G, Assanelli E, Grazi M, Campodonico J et al. The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. N Engl J Med 2003;349:1333-40.